Drug Trial Radar · NCT04994912
First in Human Study of EI-001 Monoclonal Antibody in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Jun 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
35
Actual
Start
Oct 1, 2021
Primary completion
Jan 7, 2025
Study completion Feb 18, 2025
Sponsor
- Lead sponsor
- Elixiron Immunotherapeutics (Hong Kong) Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 6, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A First-in-Human, Phase 1, Randomized, Double-Blind, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of EI-001 in Healthy Volunteers.
Conditions
- Healthy
Interventions
EI-001Drug
EI-001 IV infusion
PlaceboOther
Placebo IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- safety assessmentTime frame: Day 1
- safety assessmentTime frame: Day 1
- safety assessmentTime frame: Day 1
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Nucleus Network Pty Ltd
Melbourne, Victoria, Australia
Huashan Hospital of Fudan University
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.